The U.S. Food and Drug Administration (FDA) approved Hympavzi (marstacimab-hncq) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients ...
SentryBond technology could potentially extend to other medications, though FDA approval is pending. The FDA has approved oxycodone hydrochloride (RoxyBond) for the management of severe pain when ...
Oct. 18, 2024 -- The FDA has approved a new injectable treatment for adults with advanced Parkinson’s disease called Vyalev (also known as Produodopa). This new option is designed to help people ...
The FDA has approved Pfizer’s marstacimab (Hympavzi) for patients with haemophilia A without factor VIII inhibitors or haemophilia B without factor IX inhibitors. Marstacimab is the first anti ...
The US Food and Drug Administration (FDA) approved a new oral antibiotic to treat uncomplicated urinary tract infections (uUTIs). Orlynvah (sulopenem etzadroxil and probenecid) is a broad-spectrum ...
The product is expected to be available in the first half of 2025. The Food and Drug Administration (FDA) has approved Imuldosa ™ (ustekinumab-srlf), a biosimilar to Stelara ® (ustekinumab ...
After a prior rejection, Astellas can head into the weekend celebrating a class-first FDA approval for its new gastric cancer med Vyloy. The FDA on Friday gave Vyloy (zolbetuximab) the thumbs-up ...
The US Food and Drug Administration (FDA) has approved AbbVie's VYALEV (foscarbidopa and foslevodopa) to treat motor fluctuations in adults with advanced Parkinson's disease (PD). The chronic ...
The U.S. Food and Drug Administration has approved Itovebi (inavolisib), in combination with palbociclib (Ibrance) and fulvestrant, for the treatment of adults with endocrine-resistant, PIK3CA ...
On Thursday, the FDA approved AbbVie Inc’s (NYSE:ABBV) Vyalev (foscarbidopa and foslevodopa) as the first and only subcutaneous 24-hour infusion of levodopa-based therapy for motor fluctuations ...
Optune Lua is FDA approved for use with immunotherapy or docetaxel in metastatic stage IV NSCLC post-platinum treatment. The device uses tumor treating fields to disrupt cancer cell division ...
Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The FDA approved minocycline hydrochloride extended-release capsules (Emrosi) for treating inflammatory lesions of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback